- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07639892
Antithrombotic Treatment Strategies in Cervical Artery Dissection (TREAT-CAD 2)
Antiplatelet Versus Anticoagulation TREATment Strategies in Cervical Artery Dissection - TREAT-CAD 2 - A Multicenter, Randomized, Two-arm Parallel Group, Open-label, Blinded Endpoint, Pragmatic Trial
The goal of this clinical randomised controlled trial is to compare two treatment strategies - antiplatelet treatment strategy versus anticoagulation treatment strategy - in patients with acute, ischemic Cervical Artery Dissection (CAD). The study population includes patients presenting with any (clinical or imaging) signs of cerebral ischemia due to CAD.
The trial aims to estimate the net effect of antiplatelet versus anticoagulation treatment strategies on the composite primary outcome including recurrent ischemic stroke, major bleeding, or vascular death at 90 days (±2 weeks) after randomization.
Participants will:
- be randomly allocated to antiplatelet treatment strategy or anticoagulation treatment strategy
- receive treatment according to assigned strategy for the study period of 90 days
- be followed up for 90 days (±2 weeks) after randomization
- undergo clinical assessments to monitor for stroke recurrence, bleeding events, and vascular death Participant reported outcomes will be assessed both at 90 days (±2 weeks) and 12 months (± 4 weeks) after enrolment and will also expand to measures of quality of life and mental health outcomes.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Written informed consent (according to requirements by national legislation)
Onset/visualization of acute cerebral ischemia (≤ 3 days prior to randomization) attributable to CAD (either)
- CLINICAL ISCHEMIA: onset of acute ischemic stroke (including retinal infarct) or transient ischemic attack (including amaurosis fugax) attributable to CAD OR
- ISCHEMIA WITHOUT CORRESPONDING SYMPTOMS: visualization of acute ischemic lesion on diffusion weighted imaging attributable to CAD
Clinical MRI with suitable sequences for CAD diagnosis
- available OR
- scheduled to be performed before discharge (if not performed before enrolment)
Diagnosis of Cervical Artery Dissection (i.e. extracranial carotid and/or vertebral artery) by MRI/A or CTA based on the presence of the following criteria (at least one)
- Mural hematoma OR
- Long tapering stenosis OR
- Intimal flap OR
- Double lumen OR
- Flame-like occlusion of the dissected artery
Exclusion Criteria:
- Contraindications to either antiplatelets or oral anticoagulation therapy
- Other indication than CAD for full dose oral anticoagulation
- Contraindications for performance of MRI
- Age < 18 years
- Female patients who are either pregnant or breastfeeding (pregnancy testing prior to start of treatment will follow the standard operating procedures of clinical routine at participating sites)
Thrombolysis and/or endovascular treatment (EVT) is/are not considered an exclusion criterion.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Antiplatelet Treatment Strategy
|
Includes aspirin (ASA) or clopidogrel monotherapy or dual antiplatelet therapy (ASA + clopidogrel), at the choice of the treating physician but adhering to latest ESO guideline
|
|
Experimental: Anticoagulation Treatment Strategy
|
Includes vitamin K antagonists (phenprocoumon, acenocoumarol, warfarin) with target INR 2.0-3.0 and heparin/LMWH bridging if needed or DOACs (apixaban, edoxaban, dabigatran, rivaroxaban) - at the choice of the treating physician but adhering to latest ESO guideline
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Net effect of antiplatelet treatment strategy versus anticoagulation treatment strategy
Periodo de tiempo: From enrollment to day 90 (± 2 weeks)
|
The primary endpoint is a composite of the occurrence of (1) recurrent ischemic stroke, (2) major bleeding (extracranial or intracranial), or (3) vascular death
|
From enrollment to day 90 (± 2 weeks)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Occurrence of each single component of the primary composite outcome measure
Periodo de tiempo: From enrollment to day 90 (± 2 weeks)
|
From enrollment to day 90 (± 2 weeks)
|
|
|
- Functional neurological outcome (mRS)
Periodo de tiempo: From enrollment to day 90 (± 2 weeks)
|
absolute difference and shift in favorable outcome (defined as mRS ≤ 2)
|
From enrollment to day 90 (± 2 weeks)
|
|
All-cause mortality
Periodo de tiempo: From enrollment to day 90 (± 2 weeks)
|
From enrollment to day 90 (± 2 weeks)
|
|
|
Recurrence of Cervical Artery Dissection
Periodo de tiempo: From enrollment to day 90 (± 2 weeks)
|
From enrollment to day 90 (± 2 weeks)
|
|
|
Patient-reported outcome measure on global health (PROMIS-10)
Periodo de tiempo: From enrollment to day 90 (± 2 weeks)
|
From enrollment to day 90 (± 2 weeks)
|
|
|
Health related quality of life (EQ-5D Visual Analog scale)
Periodo de tiempo: From enrollment to day 90 (± 2 weeks)
|
From enrollment to day 90 (± 2 weeks)
|
Colaboradores e Investigadores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
- 2026-01009
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .